More breast cancers were detected in BRCA1 carriers than in BRCA2 patients (1% RRM vs. 27% surveillance in BRCA1; 0% RRM vs. 19% surveillance in BRCA2). This evidence concerns the gene BRCA2 and breast carcinoma.